Table 4. Multivariate survival analysis of clinicopathological factors in 92 EC patients.
|
Variable |
Univariate analysis crude HR (95% CI) | P value | Multivariate adjusted HR (95% CI) | P value |
|---|---|---|---|---|
| Age (years) | 1.04 (1.01–1.07)* | 0.024 | 1.03 (0.99–1.06) | 0.130 |
| ALDH1 expressiona | ||||
| Low | 1.00 (Ref.) | |||
| High | 2.28 (1.04–5.03)* | 0.041 | — | |
| CD44 expressionb | ||||
| − (negative) | 1.00 (Ref.) | |||
| + (positive) | 2.25 (1.04–4.87)* | 0.040 | — | |
| ALDH1 and CD44 expression | ||||
| Both ≤median | 1.00 (Ref.) | 1.00 (Ref.) | ||
| At least one >median | 2.23 (0.79–6.33) | 0.133 | 2.14 (0.66–6.78) | 0.204 |
| Both >median | 4.61 (1.54–13.78)** | 0.006 | 3.42 (0.97–12.05)# | 0.056 |
| FIGO Stage | ||||
| I, II | 1.00 (Ref.) | 1.00 (Ref.) | ||
| III, IV | 2.56 (1.14–5.75)* | 0.022 | 1.50 (0.60–3.76) | 0.382 |
| Nuclear grade | ||||
| Grade 1 | 1.00 (Ref.) | |||
| Grade 2 | 0.93 (0.30–2.84) | 0.895 | — | |
| Grade 3 | 3.21 (1.33–7.78)* | 0.010 | — | |
| Histological type | ||||
| Type I EC (EmAC G1 and G2) + MC | 1.00 (Ref.) | 1.00 (Ref.) | ||
| Type II EC (CC, SC) + EmAC G3 | 3.31 (1.53–7.16)** | 0.002 | 2.76 (1.09–6.86)* | 0.032 |
aLow expression of ALDH1 is defined as ≤10; high expression of ALDH1 is defined as >10.
bCD44-negative is defined as score = 0; CD44-positive is defined as score >0.
CI: confidence interval; EC: endometrial cancer; HR: hazard ratio; Ref: reference group; EmAC: endometrioid adenocarcinoma; MC: mucinous carcinoma; CC: clear cell carcinoma; SC: serous carcinoma.
#p<0.1
*p<0.05
**p<0.001.